anticorps RASSF1, anticorps zgc:92505, anticorps wu:fc17f02, anticorps zgc:112224, anticorps 123F2, anticorps NORE2A, anticorps RASSF1A, anticorps RDA32, anticorps REH3P21, anticorps AA536941, anticorps AU044980, anticorps Rassf1A, anticorps Rassf1B, anticorps Rassf1C, anticorps NPR2-like, GATOR1 complex subunit, anticorps Ras association (RalGDS/AF-6) domain family 1, anticorps Ras association domain family member 1, anticorps putative rassf1, anticorps Ras association domain family member 1 L homeolog, anticorps Ras association (RalGDS/AF-6) domain family member 1, anticorps NPRL2, anticorps rassf1, anticorps RASSF1, anticorps Smp_157340, anticorps rassf1.L, anticorps Rassf1
Sujet
The tumor suppressor gene RASSF1A (3p21.3), human Ras association domain family 1A, is expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, small intestine, colon, and peripheral blood leukocytes. RASSF1A expression is inhibited by hypermethylation of the CpG island including the promoter and early transcribed regions of the human RASSF1A gene. Hypermethylated RASSF1A promoter is observed in primary tumors. Furthermore, RASSF1A is related with cell cycle regulation, apoptosis and microtubule stability.